182
5 Future Possibilities
Abdeen S, Kunkle T, Salim N et al. (2018) Sulfonamido-2-arylbenzoxazole GroEL/ES inhibitors are
potent antibacterials against methicillin-resistant Staphylococcus aureus (MRSA). J Med Chem
61(16):7345–7357
Åberg V, Almqvist F (2007) Pilicides-small molecules targeting bacterial virulence. Org Biomol
Chem 5 (12):1827–1834
Ahmad I, Ahmad S, Rumbaugh KP (eds) (2020) Antibacterial drug discovery to combat MDR:
Natural compounds, nanotechnology and novel synthetic sources. Springer Verlag, Singapore
Alexander MK, Miu A, Oh A et al. (2018) Disrupting Gram-negative bacterial outer membrane
biosynthesis through inhibition of the lipopolysaccharide transporter MsbA. Antimicrob Agents
Chemother 62 (11):e01142–01118
Alix J-H (2013) Targeting HSP70 to fight cancer and bad bugs: One and the same battle? In:
Gualerzi CO, Brandi L, Fabbretti A et al. (eds) Antibiotics: Targets, mechanisms and resistance.
Wiley-VCH Verlag GmbH, Weinheim, pp 525–538
Altieri AS, Kelman Z (2018) DNA sliding clamps as therapeutic targets. Front Microbiol 5: Article
87
Anju CP, Subhramanian S, Sizochenko N et al. (2019) Multiple e-Pharmacophore modeling to
identify a single molecule that could target both streptomycin and paromomycin binding sites for
30S ribosomal subunit inhibition. J Biomol Struct Dyn 37 (6):1582–1596
Arvanitis M, Glavis-Bloom J, Mylonakis E (2013) C. elegans for anti-infective discovery. Curr
Opin Pharmacol 13 (5):769–774
Baell JB, Leaver DJ, Hermans SJ et al. (2018) Inhibitors of histone acetyltransferases KAT6A/B
induce senescence and arrest tumour growth. Nature 560:253–257
Baell JB (2021) Personal accounts of Australian drug discovery at the public-private interface. Aust
J Chem 74:16–27
Begley DW, Fox D, 3rd, Jenner D et al. (2014) A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins. Antimicrob Agents Chemother 58
(3):1458–1467
Benkendorff K (2013) Natural product research in the Australian marine invertebrate Dicathais
orbita. Mar Drugs 11:1370–1398
Benkendorff K, Bremner JB, Davis AR (2000) Tyrian purple precursors in the egg masses of the
Australian muricid, Dicathais orbita: A possible defensive role. J Chem Ecol 26(4):1037–1050
Biswas NN, Iskander GM, Mielczarek M et al. (2018) Alkyne-substituted fimbrolide analogues as
novel bacterial quorum-sensing inhibitors. Aust J Chem 71 (9):708–715
Blount KF, Breaker RR (2006) Riboswitches as antibacterial drug targets. Nat Biotechnol 24
(12):1558–1564
Boström J, Brown DG, Young RJ et al. (2018) Expanding the medicinal chemistry synthetic toolbox.
Nat Rev Drug Discov 17:709–727
Boyaci H, Chen J, Lilic M et al. (2018) Fidaxomicin jams Mycobacterium tuberculosis RNA
polymerase motions needed for initiation via RbpA contacts. Elife 7:e34823
Branson TR, Turnbull WB (2013) Bacterial toxin inhibitors based on multivalent scaffolds. Chem
Soc Rev 42 (11):4613–4622
Brown DG, Boström J (2016) Analysis of past and present synthetic methodologies on medicinal
chemistry: where have all the new reactions gone? J Med Chem 59 (10):4443–4458
Brüssow H (2017) Infection therapy: the problem of drug resistance - and possible solutions. Microb
Biotechnol 10 (5):1041–1046
Buonanno F, Anesi A, Guella G et al. (2017) Blepharismins used for chemical defense in two ciliate
species of the genus Blepharisma, B. stoltei and B. undulans (Ciliophora: Heterotrichida). Eur
Zool J 84(1):402–409
Buroni S, Scoffone VC, Fumagalli M et al. (2018) Investigating the mechanism of action of
diketopiperazines inhibitors of the Burkholderia cenocepacia quorum sensing synthase Cepl:
A site-directed mutagenesis study. Front Pharmacol 9: Article 836
Calvert MB, Jumde VR, Titz A (2018) Pathoblockers or antivirulence drugs as a new option for the
treatment of bacterial infections. Beilstein J Org Chem 14:2607–2617
5 Future Possibilities
Abdeen S, Kunkle T, Salim N et al. (2018) Sulfonamido-2-arylbenzoxazole GroEL/ES inhibitors are
potent antibacterials against methicillin-resistant Staphylococcus aureus (MRSA). J Med Chem
61(16):7345–7357
Åberg V, Almqvist F (2007) Pilicides-small molecules targeting bacterial virulence. Org Biomol
Chem 5 (12):1827–1834
Ahmad I, Ahmad S, Rumbaugh KP (eds) (2020) Antibacterial drug discovery to combat MDR:
Natural compounds, nanotechnology and novel synthetic sources. Springer Verlag, Singapore
Alexander MK, Miu A, Oh A et al. (2018) Disrupting Gram-negative bacterial outer membrane
biosynthesis through inhibition of the lipopolysaccharide transporter MsbA. Antimicrob Agents
Chemother 62 (11):e01142–01118
Alix J-H (2013) Targeting HSP70 to fight cancer and bad bugs: One and the same battle? In:
Gualerzi CO, Brandi L, Fabbretti A et al. (eds) Antibiotics: Targets, mechanisms and resistance.
Wiley-VCH Verlag GmbH, Weinheim, pp 525–538
Altieri AS, Kelman Z (2018) DNA sliding clamps as therapeutic targets. Front Microbiol 5: Article
87
Anju CP, Subhramanian S, Sizochenko N et al. (2019) Multiple e-Pharmacophore modeling to
identify a single molecule that could target both streptomycin and paromomycin binding sites for
30S ribosomal subunit inhibition. J Biomol Struct Dyn 37 (6):1582–1596
Arvanitis M, Glavis-Bloom J, Mylonakis E (2013) C. elegans for anti-infective discovery. Curr
Opin Pharmacol 13 (5):769–774
Baell JB, Leaver DJ, Hermans SJ et al. (2018) Inhibitors of histone acetyltransferases KAT6A/B
induce senescence and arrest tumour growth. Nature 560:253–257
Baell JB (2021) Personal accounts of Australian drug discovery at the public-private interface. Aust
J Chem 74:16–27
Begley DW, Fox D, 3rd, Jenner D et al. (2014) A structural biology approach enables the development of antimicrobials targeting bacterial immunophilins. Antimicrob Agents Chemother 58
(3):1458–1467
Benkendorff K (2013) Natural product research in the Australian marine invertebrate Dicathais
orbita. Mar Drugs 11:1370–1398
Benkendorff K, Bremner JB, Davis AR (2000) Tyrian purple precursors in the egg masses of the
Australian muricid, Dicathais orbita: A possible defensive role. J Chem Ecol 26(4):1037–1050
Biswas NN, Iskander GM, Mielczarek M et al. (2018) Alkyne-substituted fimbrolide analogues as
novel bacterial quorum-sensing inhibitors. Aust J Chem 71 (9):708–715
Blount KF, Breaker RR (2006) Riboswitches as antibacterial drug targets. Nat Biotechnol 24
(12):1558–1564
Boström J, Brown DG, Young RJ et al. (2018) Expanding the medicinal chemistry synthetic toolbox.
Nat Rev Drug Discov 17:709–727
Boyaci H, Chen J, Lilic M et al. (2018) Fidaxomicin jams Mycobacterium tuberculosis RNA
polymerase motions needed for initiation via RbpA contacts. Elife 7:e34823
Branson TR, Turnbull WB (2013) Bacterial toxin inhibitors based on multivalent scaffolds. Chem
Soc Rev 42 (11):4613–4622
Brown DG, Boström J (2016) Analysis of past and present synthetic methodologies on medicinal
chemistry: where have all the new reactions gone? J Med Chem 59 (10):4443–4458
Brüssow H (2017) Infection therapy: the problem of drug resistance - and possible solutions. Microb
Biotechnol 10 (5):1041–1046
Buonanno F, Anesi A, Guella G et al. (2017) Blepharismins used for chemical defense in two ciliate
species of the genus Blepharisma, B. stoltei and B. undulans (Ciliophora: Heterotrichida). Eur
Zool J 84(1):402–409
Buroni S, Scoffone VC, Fumagalli M et al. (2018) Investigating the mechanism of action of
diketopiperazines inhibitors of the Burkholderia cenocepacia quorum sensing synthase Cepl:
A site-directed mutagenesis study. Front Pharmacol 9: Article 836
Calvert MB, Jumde VR, Titz A (2018) Pathoblockers or antivirulence drugs as a new option for the
treatment of bacterial infections. Beilstein J Org Chem 14:2607–2617